Metabolite Profile of Treatment-Naive Metabolic Syndrome Subjects in Relation to Cardiovascular Disease Risk.
cardiovascular disease
lipolysis
metabolic syndrome
metabolomics
phospholipids
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
13 Apr 2021
13 Apr 2021
Historique:
received:
12
02
2021
revised:
02
04
2021
accepted:
10
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Metabolic syndrome (MetSyn) is an important risk factor for type 2 diabetes and cardiovascular diseases (CVD). This study aimed to find distinct plasma metabolite profiles between insulin-resistant and non-insulin resistant subjects with MetSyn and evaluate if MetSyn metabolite profiles are related to CVD risk and lipid fluxes. In a cross-sectional study, untargeted metabolomics of treatment-naive males with MetSyn (
Identifiants
pubmed: 33924347
pii: metabo11040236
doi: 10.3390/metabo11040236
pmc: PMC8069178
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Hartstichting
ID : 2018.27
Organisme : ZonMw
ID : 016.146.327
Pays : Netherlands
Références
Ann Intern Med. 2005 Nov 15;143(10):722-8
pubmed: 16287793
J Am Coll Cardiol. 2007 Jan 30;49(4):403-14
pubmed: 17258085
Nature. 2006 Dec 14;444(7121):881-7
pubmed: 17167477
Cell. 2018 Nov 1;175(4):947-961.e17
pubmed: 30401435
PLoS One. 2016 Nov 18;11(11):e0166682
pubmed: 27861548
Cardiovasc Diabetol. 2018 Aug 31;17(1):122
pubmed: 30170598
Am J Manag Care. 2016 Jun;22(7 Suppl):s176-85
pubmed: 27356115
Diabetes Care. 2016 May;39(5):833-46
pubmed: 27208380
Nature. 2011 Apr 7;472(7341):57-63
pubmed: 21475195
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
Ann N Y Acad Sci. 1959 Sep 25;82:420-30
pubmed: 13833973
Diabetes Care. 2012 Jul;35(7):1605-10
pubmed: 22511259
Obesity (Silver Spring). 2010 Sep;18(9):1695-700
pubmed: 20111019
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
Gastroenterology. 2012 Oct;143(4):913-6.e7
pubmed: 22728514
Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):139-43
pubmed: 21297467
Diabetes. 2013 Jan;62(1):1-8
pubmed: 23258903
Metabolomics. 2019 Feb 12;15(2):23
pubmed: 30830468
Int J Obes (Lond). 2015 Dec;39(12):1703-9
pubmed: 26155920
Mol Cell Biochem. 2019 Oct;460(1-2):195-203
pubmed: 31280435
Am J Physiol Endocrinol Metab. 2016 Mar 1;310(5):E323-31
pubmed: 26714848
Circulation. 2015 Mar 3;131(9):774-85
pubmed: 25573147
Nat Rev Endocrinol. 2017 Feb;13(2):79-91
pubmed: 27767036
J Lipid Res. 2013 Oct;54(10):2898-908
pubmed: 23868910
J Am Soc Nephrol. 2005 Jul;16(7):2134-40
pubmed: 15901764
Nutrients. 2020 Jul 31;12(8):
pubmed: 32752028
Lipids. 1997 Jul;32(7):707-14
pubmed: 9252958
Expert Rev Endocrinol Metab. 2020 Jan;15(1):13-27
pubmed: 32066294
FASEB J. 2015 Jan;29(1):336-45
pubmed: 25342132
Compr Physiol. 2013 Jan;3(1):1-58
pubmed: 23720280
Cell. 2020 Mar 5;180(5):862-877.e22
pubmed: 32142679
Am J Physiol. 1979 Sep;237(3):E214-23
pubmed: 382871
Obes Sci Pract. 2020 Feb 07;6(3):340-349
pubmed: 32523723
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Biomed J. 2017 Oct;40(5):257-262
pubmed: 29179880
Diabetes Care. 2008 Sep;31(9):1898-904
pubmed: 18591398
Metabolomics. 2018 Aug 31;14(9):117
pubmed: 30830367
Cell. 2010 Sep 3;142(5):687-98
pubmed: 20813258
PLoS One. 2013 Sep 27;8(9):e74341
pubmed: 24086336
Lancet. 2009 Mar 28;373(9669):1083-96
pubmed: 19299006
Appl Physiol Nutr Metab. 2013 Mar;38(3):334-40
pubmed: 23537027
Diabetes. 1987 Aug;36(8):914-24
pubmed: 3297886
Cell Metab. 2012 May 2;15(5):595-605
pubmed: 22560212
Mol Cell Endocrinol. 2010 May 14;320(1-2):25-33
pubmed: 20144685